HARD DECISIONS IN INTENSIVE CARE UNIT

Intensivecareunitkapak

SEPSIS AND RESISTANT INFECTIONS

Korhan Kollu

Konya City Hospital, Department of Internal Medicine, Konya, Türkiye

Kollu K. Sepsis and Resistant Infections. In: Turan S, editor. Hard Decisions in Intensive Care Unit. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.351-363.

ABSTRACT

Sepsis is a life-threatening condition characterized by acute organ dysfunction resulting from a dysregulated host response to infection, posing a significant challenge to global healthcare systems. The continuous evolution of definitions and diagnostic criteria reflects the complexity of this clinical syndrome. The management of sepsis encompasses timely diagnosis, infection control, restoration of perfusion, and organ support. Recently, significant advancements have been made in the modulation of immune response and the development of personalized therapeutic approaches. However, the increasing prevalence of multidrug-resistant (MDR) infections in intensive care units further exacerbates these challenges. These infections, predominantly caused by ESKAPE pathogens and Candida auris, are associated with prolonged hospital stays, increased mortality rates, and substantial healthcare costs. Addressing sepsis and MDR infections requires an integrated approach emphasizing antimicrobial stewardship, infection control measures, and the development of novel therapeutic strategies.

Keywords: Sepsis; Intensive care unit; Multi-drug resistant; Gram-negative bacterial infections; Gram-positive bacterial infections; Candida auris

Referanslar

  1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest.1992;101(6):1644-1655. [Crossref]  [PubMed]
  2. Meyer NJ, Prescott HC. Sepsis and Septic Shock. New England Journal of Medicine. 2024;391(22):2133-2146. [Crossref]  [PubMed]
  3. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/ SIS international sepsis definitions conference. Intensive Care Med. 2003;29:530-538. [Crossref]  [PubMed]
  4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801-10. [Crossref]  [PubMed]  [PMC]
  5. Antonucci E, Polo T, Giovini M, Girardis M, Martin-Loeches I, Nielsen ND, et al. Refractory septic shock and alternative wordings: a systematic review of literature. J Crit Care.2023;75:154258. [Crossref]  [PubMed]
  6. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395: 200-11. [Crossref]  [PubMed]
  7. Liang L, Moore B, Soni A. National inpatient hospital costs: the most expensive conditions by payer, 2017. Statistical brief no. 261. Rockville, MD: Agency for Healthcare Research and Quality, 2020. [Link]
  8. Kalantar KL, Neyton L, Abdelghany M, Mick E, Jauregui A, Caldera S, et al. Integrated host-microbe plasma metagenomics for sepsis diagnosis in a prospective cohort of critically ill adults. Nat Microbiol. 2022;7:1805-1816. [Crossref]  [PubMed]  [PMC]
  9. Timsit J-F, Ruppé E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill patients: an expert statement. Intensive Care Med. 2020;46:266-284. [Crossref]  [PubMed]  [PMC]
  10. Shankar-Hari M, Calandra T, Soares MP, Bauer M, Wiersinga WJ, Prescott HC, et al. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. Lancet Respir Med. 2024;12:323-336. [Crossref]  [PubMed]
  11. Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard AL, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 2006; 32:1175-1183. [Crossref]  [PubMed]
  12. Reyes M, Filbin MR, Bhattacharyya RP, Sonny A, Mehta A, Billman K, et al. Plasma from patients with bacterial sepsis or severe COVID-19 induces suppressive myeloid cell production from hematopoietic progenitors in vitro. Sci Transl Med. 2021;13: eabe9599-eabe9599. [Crossref]  [PubMed]  [PMC]
  13. Lindell RB, Zhang D, Bush J, Wallace DC, Rabinowitz JD, Lu W, et al. Impaired lymphocyte responses in pediatric sepsis vary by pathogen type and are associated with features of immunometabolic dysregulation. Shock. 2022; 57:191-199. [Crossref]  [PubMed]  [PMC]
  14. Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care. 2019;23:16-16. [Crossref]  [PubMed]  [PMC]
  15. Mastellos DC, Hajishengallis G, Lambris JD. A guide to complement biology, pathology and therapeutic opportunity. Nat Rev Immunol. 2024;24:118-141. [Crossref]  [PubMed]
  16. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. 1996; 707-710. [Crossref]  [PubMed]
  17. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock. Crit Care Med. 2021;49(11):e1063-e1143. [Crossref]  [PubMed]  [PMC]
  18. Gregoriano C, Heilmann E, Molitor A, & Schuetz P. Role of procalcitonin use in the management of sepsis. Journal of thoracic disease. 2020;12(Suppl 1):S5. [Crossref]  [PubMed]  [PMC]
  19. Barlam Tf, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Executive Summary: ımplementing an Antibiotic Stewardship Program: Guidelines by the infectious Diseases Society of America and the Society for Health care Epidemiology of America. Clin infect Dis. 2016; 62:1197-202. [Crossref]  [PubMed]
  20. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS et al. Time to treatment and mortality during mandated emergency care for sep¬sis. N Engl J Med. 2017;376:2235-44. [Crossref]  [PubMed]  [PMC]
  21. Lat I, Coopersmith CM, De Backer D. The Surviving Sepsis Campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients. Crit Care Med. 2021;49:623-635. [Crossref]  [PubMed]  [PMC]
  22. The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network. Early restrictive or liberal fluid management for sepsis-induced hypotension. N Engl J Med. 2023;388:499-510. [Crossref]  [PubMed]  [PMC]
  23. Aya HD, Rhodes A, Chis Ster I, Fletcher N, Grounds RM, Cecconi M. Hemodynamic effect of different doses of fluids for a fluid challenge: a quasi-randomized controlled study. Crit Care Med. 2017;45(2):e161-e168. [Crossref]  [PubMed]
  24. Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA. 2016;316:1298-1309. [Crossref]  [PubMed]
  25. Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, et al. Fluid response evaluation in sepsis hypotension and shock: a randomized clinical trial. Chest. 2020;158:1431-1445. [Crossref]  [PubMed]  [PMC]
  26. Lamontagne F, Richards-Belle A, Thomas K, Harrison DA, Sadique MZ, Grieve RD, et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. JAMA. 2020;323:938-949. [Crossref]  [PubMed]  [PMC]
  27. Antonucci E, Polo T, Giovini M, Girardis M, Martin-Loeches I, Nielsen ND, et al. Refractory septic shock and alternative wordings: a systematic review of literature. J Crit Care. 2023; 75:154258. [Crossref]  [PubMed]
  28. Gu W-J, Zhang Z, Bakker J. Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials. Intensive Care Med. 2015;41:1862-1863. [Crossref]  [PubMed]
  29. Hernández G, Ospina-Tascón GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019;321:654-664. [Crossref]  [PubMed]
  30. Fang F, Zhang Y, Tang J, Lunsford LD, Li T, Tang R, et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis. JAMA Intern Med. 2019;179:213-223. [Crossref]  [PubMed]  [PMC]
  31. Bosch NA, Teja B, Law AC, Pang B, Jafarzadeh SR, Walkey AJ. Comparative effectiveness of fludrocortisone and hydrocortisone vs hydrocortisone alone among patients with septic shock. JAMA Intern Med. 2023;183:451-459. [Crossref]  [PubMed]  [PMC]
  32. Teja B, Berube M, Pereira TV, Law AC, Schanock C, Pang B, et al. Effectiveness of fludrocortisone plus hydrocortisone versus hydrocortisone alone in septic shock: a systematic review and network meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 2024;209:1219-1228. [Crossref]  [PubMed]  [PMC]
  33. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine. 2008;358(9):877-887. [Crossref]  [PubMed]
  34. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017;377:419-430. [Crossref]  [PubMed]
  35. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical microbiology and infection. 2012;18(3):268-281. [Crossref]  [PubMed]
  36. Campion M, Scully G. Antibiotic use in the intensive care unit: optimization and de-escalation. Journal of intensive care medicine. 2018;33(12):647-655. [Crossref]  [PubMed]
  37. Chernov VM, Chernova OA, Mouzykantov AA, Lopukhov LL, Aminov RI. Omics of antimicrobials and antimicrobial resistance. Expert opinion on drug discovery. 2019;14(5):455-468. [Crossref]  [PubMed]
  38. Pandey R, Mishra SK, Shrestha A. Characterisation of ESKAPE Pathogens with Special Reference to Multidrug Resistance and Biofilm Production in a Nepalese Hospital. Infect. Drug Resist. 2021;14:2201-2212. [Crossref]  [PubMed]  [PMC]
  39. Kollef MH, Zilberberg MD, Shorr AF, Vo L, Schein J, Micek ST, et al. Epidemiology, Microbiology and Outcomes of Healthcare-Associated and Community-Acquired Bacteremia: A Multicenter Cohort Study. J. Infect. 2011;62:130-135. [Crossref]  [PubMed]
  40. WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022- 020 data. Copenhagen: WHO Regional Office for Europe; 2022. [Link]
  41. Capsoni N, Bellone P, Aliberti S, Sotgiu G, Pavanello D, Visintin B, et al. Prevalence, Risk Factors and Outcomes of Patients Coming from the Community with Sepsis Due to Multidrug Resistant Bacteria. Multidiscip. Respir. Med. 2019;14:23. [Crossref]  [PubMed]  [PMC]
  42. Kumar NR, Balraj TA, Kempegowda SN, Prashant A. Multidrug-resistant sepsis: A critical healthcare challenge. Antibiotics. 2024;13(1):46. [Crossref]  [PubMed]  [PMC]
  43. Vakkalanka JP, Harland KK, Swanson MB, Mohr NM. Clinical and Epidemiological Variability in Severe Sepsis: An Ecological Study. J. Epidemiol. Community Health. 2018;72:741-745. [Crossref]  [PubMed]  [PMC]
  44. Du D, Wang-Kan X, Neuberger A, Van Veen HW, Pos KM, Piddock LJ, et al. Multidrug Efflux Pumps: Structure, Function and Regulation. J Nat. Rev. Microbiol. 2018;16:523-539. [Crossref]  [PubMed]
  45. Friedrich AW. Control of Hospital Acquired Infections and Antimicrobial Resistance in Europe: The Way to Go. Wien. Med. Wochenschr. 2019;169:25-30. [Crossref]  [PubMed]  [PMC]
  46. Boomer JS, Green JM, Hotchkiss RS. The Changing Immune System in Sepsis: Is Individualized Immuno-Modulatory Therapy the Answer? Virulence. 2014;5:45-56. [Crossref]  [PubMed]  [PMC]
  47. Venet F, Monneret G. Advances in the Understanding and Treatment of Sepsis-Induced Immunosuppression. Nat. Rev. Nephrol. 2018;14:121-137. [Crossref]  [PubMed]
  48. Salam MT, Bari KB, Rahman MM., Gafur DMM, Faruk MO, Akter K, et al. Emergence of antibiotic-resistant infections in ICU patients. Journal of Angiotherapy. 2024;8(5):1-9. [Crossref]  [PubMed]  [PMC]
  49. CDC. 2019. Antibiotic resistance threats in the United States. U.S. Department of Health and Human Services, CDC, Atlanta, GA. [Link]
  50. Lyman M, Forsberg K, Reuben J, Dang T, Free R, Seagle EE, et al. Notes from the field: transmission of pan-resistant and Echinocandin-resistant Candida auris in health care facilities-Texas and the District of Columbia, MMWR. Morbidity and Mortality Weekly Report, January-April 2021;70.1022-1023. [Crossref]  [PubMed]  [PMC]
  51. Ugwu MC, Shariff M, Nnajide CM, Beri K, Okezie UM, Iroha IR, et al. Phenotypic and Molecular Characterization of β-Lactamases among Enterobacterial Uropathogens in Southeastern Nigeria. Canadian Journal of Infectious Diseases and Medical Microbiology. 2020(1):5843904. [Crossref]  [PubMed]  [PMC]
  52. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis. Lancet Infect. Dis. 2018; 18, 318-327. [Crossref]  [PubMed]
  53. Green RS, Gorman SK. Emergency department antimicrobial considerations in severe sepsis. Emerg. Med. Clin. N. Am. 2014; 32, 835-849. [Crossref]  [PubMed]
  54. Force IST. Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. Clin. Infect. Dis. 2017;66:1631-1635. [Crossref]  [PubMed]  [PMC]
  55. Ostrowsky B, Banerjee R, Bonomo RA, Cosgrove SE, Davidson L, Doron S, et al. Infectious Diseases Physicians: Leading theWay in Antimicrobial Stewardship. Clin. Infect. Dis. 2018;66,995-1003. [Crossref]  [PubMed]
  56. Liaskou M, Duggan C, Joynes R, Rosado H. Pharmacy's role in antimicrobial resistance and stewardship. Pharm. J. 2018; 10-1211. [Crossref]
  57. Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? Clin. Microbiol. Infect. 2017;23:793-798. [Crossref]  [PubMed]
  58. Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin. Proc. 2011;86:1113-1123. [Crossref]  [PubMed]  [PMC]
  59. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci. Transl. Med. 2012;4(148):148ra116-148ra116. [Crossref]  [PubMed]  [PMC]